Alembic Pharmaceuticals

In 1907, a chemistry professor at the M.S. University of Baroda, a colleague and a businessman set up a chemical-works company in Vadodara under the patronage of Maharaja Sayajirao Gaekwad. Alembic Chemical Works Company Ltd. began with tinctures and alcohol. More than a century later, the same name carries one of the oldest brand-equity bases in Indian pharma, run by the Amin family from the same city.

A century-old anti-infective franchise, a 21st-century US push

The early decades took Alembic through cough syrups, vitamins and sulphur drugs in the 1940s. The defining moment came in 1961 when Prime Minister Lal Bahadur Shastri inaugurated the company's penicillin plant. Anti-infectives, especially macrolides, became the commercial franchise that anchored the business for the next six decades. Bulk vitamin B12 and erythromycin came in 1971. In 1999 the parent renamed itself from Alembic Chemical Works to Alembic Ltd., and in 2010 the pharma business demerged into Alembic Pharmaceuticals, listing on BSE and NSE on 20 September 2011.

The modern story is regulated-market generics layered on top of the legacy India franchise. Alembic acquired Orit Laboratories in the US in 2017, entered Algeria via a joint venture in 2014, entered China via JV in 2019, and acquired 100 percent of Aleor Dermaceuticals in 2022 to deepen the derma layer. Between late 2024 and mid-2025 the company pulled a cluster of US FDA approvals across rivaroxaban, amlodipine plus atorvastatin, doxorubicin liposome, tretinoin and ophthalmics, taking cumulative ANDA approvals to about 223. In 2025 the US subsidiary acquired Utility Therapeutics for about US$12 million, adding the UTI drug Pivya (pivmecillinam) as a US branded franchise.

Why the commercial engine is the interesting part

By FY2025 Alembic reports revenue of about ₹6,672 crore on net income of about ₹583.42 crore, with 16,571 employees. Two engines sit under one P&L. The Indian branded business is brand-equity-led and detailing-led, anchored on the macrolide franchise that has been part of standard practice for general practitioners and ENT specialists for years. The US business is filings-led and pricing-discipline-led, operating across about 223 ANDA approvals where US generic price-erosion is a constant. FY2025 net income fell about 12 percent on softer US realisations even as ANDA approvals accelerated, which captures the operating tension between the two engines neatly.

The next chapter

The 2022 Aleor merger added specialty dermatology depth. The 2025 Utility Therapeutics deal added US branded exposure for the first time at scale. Together they suggest a deliberate shift in mix away from pure ANDA generics and towards branded specialty in both India and the US. The question the next four to eight quarters will answer is whether the new branded layer compounds fast enough to offset US generic price-erosion in the legacy ANDA portfolio.

It will not be more dashboards. The next advantage is intelligence: every Indian rep on the macrolide franchise walking in already knowing what shifted in this prescriber's brand share this fortnight, every Aleor-derma divisional head separating a state-level coverage slip from a tender shift in time to act, every US brand manager on rivaroxaban or doxorubicin liposome seeing whether early uptake was payer-access or pricing within days. The first generation of Indian pharma built access. The second built scale. The next will build intelligent commercial operations. That is the future PharmaOS is built for.